ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy. Cancer ASCO FDA Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home Biotech A standing ovation for RevMed, and caution for Akeso This is STAT’s ASCO in…
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.
Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted standing ovations, and the hoots and cheers were not held for the end.
The plenary may have passed, but ASCO isn’t over yet— we’ll be back tomorrow with our final newsletter installment, and you can catch our virtual recap on Wednesday.
Continue to STAT+ to read the full story…
US Pharma Marketing